Investigational drug · Phase 2
IDX-1197
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "IDX-1197"
First trial start
2021
Jun 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDX-1197", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IDX-1197" as an intervention, largest first.
- Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)Completed
Idience Co., Ltd.Industry
NCT04174716 · 108 participants · Start Nov 6, 2019 · Primary completion Mar 31, 2023
Drug: IDX-1197 · For: Solid Tumors; Homologous Recombination Repair Gene Mutation; Homologous Recombination Deficiency
Sites: Goyang, South Korea; Seongnam-si, South Korea; Suwon, South Korea · 19 sites in all
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerActive, not recruiting
Idience Co., Ltd.Industry
NCT04725994 · 87 participants · Start Jun 28, 2021 · Primary completion Jul 31, 2026
Drug: IDX-1197+XELOX; IDX-1197+Irinotecan · For: Gastric Cancer
Sites: Los Angeles, California; Baton Rouge, Louisiana; Boston, Massachusetts · 17 sites in all
Idience Co., Ltd.Industry
NCT05202912 · 37 participants · Start Jan 16, 2022 · Primary completion Jul 23, 2022
Drug: IDX-1197(After a meal); IDX-1197(fasting) · For: Healthy Male
Sites: Seoul, South Korea
Idience Co., Ltd.Industry
NCT03317743 · 32 participants · Start Aug 29, 2017 · Primary completion Dec 8, 2020
Drug: NOV140101 (IDX-1197) · For: Advanced Solid Tumors
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors.
Kim SB, Bae KS, Lee JL, et al. · Cancer Med 2025
- Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety.
Lee M, Je IG, Kim JE, et al. · Mol Cancer Ther 2023
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.